Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELOS-3: Tanfanercept in Dry Eye Disease
NCT05109702Phase 3Completed
- Sponsor
- HanAll Biopharma
- Start
- Nov 2021
- Primary completion
- May 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tanfanercept in dry eye disease (DED) (3 arms), sponsored by HanAll Biopharma. Primary endpoints: Change From Baseline in Central Corneal Staining Score at 57 days and Change From Baseline in Eye Dryness Score at 57 days. Started Nov 2021; status: completed.
02
Drugs
tanfanercept
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05109702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05109702.